

- [21] Y. Li, M. Choi, G. Cavey, J. Daugherty, K. Suino, A. Kovach, N.C. Bingham, S.A. Kliewer, H.E. Xu, Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1, *Mol. Cell* 17 (2005) 491–502.
- [22] W. Wang, C. Zhang, A. Marimuthu, H.I. Krupka, M. Tabrizi, R. Shelloe, U. Mehra, K. Eng, H. Nguyen, C. Settachatgul, et al., The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1, *Proc. Natl. Acad. Sci. USA* 102 (2005) 7505–7510.
- [23] E.P. Sablin, I.N. Krylova, R.J. Fletterick, H.A. Ingraham, Structural basis for ligand-independent activation of the orphan nuclear receptor LRH-1, *Mol. Cell* 11 (2003) 1575–1585.

# Insulin-like Growth Factor 1/Insulin Signaling Activates Androgen Signaling through Direct Interactions of Foxo1 with Androgen Receptor<sup>\*[5]</sup>

Received for publication, November 9, 2006, and in revised form, December 15, 2006. Published, JBC Papers in Press, January 2, 2007, DOI 10.1074/jbc.M610447200

WuQiang Fan<sup>‡</sup>, Toshihiko Yanase<sup>†1</sup>, Hidetaka Morinaga<sup>‡</sup>, Taijiro Okabe<sup>‡</sup>, Masatoshi Nomura<sup>‡</sup>, Hiroaki Daitoku<sup>5</sup>, Akiyoshi Fukamizu<sup>5</sup>, Shigeaki Kato<sup>1</sup>, Ryoichi Takayanagi<sup>‡</sup>, and Hajime Nawata<sup>||</sup>

From the <sup>‡</sup>Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, <sup>5</sup>Center for Tsukuba Advanced Research Alliance, Graduate School of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8577, <sup>1</sup>Institute of Molecular and Cellular Biosciences, Graduate School of Agricultural and Life Sciences, University of Tokyo, Tokyo 113-0032, and <sup>||</sup>Graduate School of Medical Science, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan

The androgen-androgen receptor (AR) system plays vital roles in a wide array of biological processes, including prostate cancer development and progression. Several growth factors, such as insulin-like growth factor 1 (IGF1), can induce AR activation, whereas insulin resistance and hyperinsulinemia are correlated with an elevated incidence of prostate cancer. Here we report that Foxo1, a downstream molecule that becomes phosphorylated and inactivated by phosphatidylinositol 3-kinase/Akt kinase in response to IGF1 or insulin, suppresses ligand-mediated AR transactivation. Foxo1 reduces androgen-induced AR target gene expressions and suppresses the *in vitro* growth of prostate cancer cells. These inhibitory effects of Foxo1 are attenuated by IGF1 but are enhanced when it is rendered Akt-nonphosphorylatable. Foxo1 interacts directly with the C terminus of AR in a ligand-dependent manner and disrupts ligand-induced AR subnuclear compartmentalization. Foxo1 is recruited by liganded AR to the chromatin of AR target gene promoters, where it interferes with AR-DNA interactions. IGF1 or insulin abolish the Foxo1 occupancy of these promoters. Of interest, a positive feedback circuit working locally in an autocrine/intracrine manner may exist, because liganded AR up-regulates IGF1 receptor expression in prostate cancer cells, presumably resulting in higher IGF1 signaling tension and further enhancing the functions of the receptor itself. Thus, Foxo1 is a novel corepressor for AR, and IGF1/insulin signaling may confer stimulatory effects on AR by attenuating Foxo1 inhibition. These results highlight the potential involvement of metabolic syndrome and hyperinsulinemia in prostate diseases and further suggest that intervention of IGF1/insulin-phosphatidylinositol 3-kinase-Akt signaling may be of clinical value for prostate diseases.

Androgen receptor (AR)<sup>2</sup> is a member of a nuclear receptor superfamily and functions as a ligand-dependent transcription factor. The androgen-AR system mediates male sexual differentiation in the uterus, sperm production at puberty, prostate development in the adult, and primary prostate cancer (PC) growth in patients with PC (1). PC is the most common malignancy in men worldwide and the second leading cause of cancer-related mortality in the United States (2). The fact that over 70% of PCs rely on androgen stimulation for growth sets the basis for androgen ablation therapy, which is initially effective but invariably results in treatment resistance after a period of time (3). The disease is then referred to as androgen-independent PC and progresses to a fatal outcome. Recent loss-of-function studies have revealed that AR still plays a key role in hormone-refractory progression of PC (4, 5). An adaptation of AR signaling in order to function under low or absent androgen levels may occur (6). Among the various suggested mechanisms by which AR may be reactivated in a low androgen environment (7), signaling by growth factors, especially insulin-like growth factor 1 (IGF1), is reportedly of significant importance (8–11). High IGF1 serum levels are correlated with an increased risk of PC (8, 9), whereas IGF1 enhances AR transactivation under very low or absent androgen levels (12, 13) and promotes PC cell proliferation (10). Recent studies have also revealed that high serum insulin levels are associated with an increased incidence of PC (14, 15), although there is a lack of mechanistic studies implicating insulin signaling in the regulation of AR function.

Foxo1, also known as FKHR, together with other two homologs, FKHL1 and AFX, belong to the Foxo subfamily of the forkhead transcription factor family, which includes a large array of transcription factors characterized by the presence of a

\* This work was supported by a grant-in-aid for the "Mechanism of Sex Differentiation" and a grant from the 21st Century COE Program from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[5] The on-line version of this article (available at <http://www.jbc.org>) contains supplemental Figs. 1–9.

<sup>1</sup> To whom correspondence should be addressed. Tel.: 81-92-642-5280; Fax: 81-92-642-5287; E-mail: yanase@intmed3.med.kyushu-u.ac.jp.

<sup>2</sup> The abbreviations used are: AR, androgen receptor; hAR, human AR; ARE, androgen-response element; ChIP, chromatin immunoprecipitation; DHT, 5 $\alpha$ -dihydrotestosterone; ER, estrogen receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GR, glucocorticoid receptor; IGF1, insulin-like growth factor 1; IGF1R, insulin-like growth factor 1 receptor; MMTV, mouse mammary tumor virus; PC, prostate cancer; PI3K, phosphatidylinositol 3-kinase; PR, progesterone receptor; PSA, prostate-specific antigen; PTEN, human phosphatase and tensin homolog (mutated in multiple advanced cancers 1); EIA, enzyme immunoassay; PBS, phosphate-buffered saline; ANOVA, analysis of variance; HI, heterogeneity index.

## Foxo1 Represses AR

conserved 110-amino acid winged helix DNA-binding domain (16). Foxo subfamily members play important roles in cell cycle regulation and apoptosis, as well as in metabolic homeostasis (17).

Phosphatidylinositol 3-kinase (PI3K)/Akt signaling, which is activated by both liganded IGF1 receptor (IGF1R) and insulin receptor, phosphorylates each of the Foxo proteins at three different Ser/Thr residues (17). The phosphorylated Foxo proteins become inactive and are exported from the nucleus. Subsequently, they become sequestered in the cytoplasm, where they interact with 14-3-3 protein.

In this study, we observe that Foxo1, which is endogenously expressed in PC cells, can interact with AR via the C terminus of the receptor in a ligand-dependent manner and suppress ligand-induced AR transactivation. Foxo1 impaired AR signaling by interfering with ligand-induced AR nuclear translocation and subnuclear compartmentalization as well as receptor-target gene promoter interactions. Furthermore, IGF1/insulin-PI3K/Akt pathway-induced phosphorylation of Foxo1 ameliorated the suppression. Intriguingly, liganded AR stimulated IGF1R expression, suggesting the presence of local positive feedback between IGF1 and AR signaling in PC cells.

### EXPERIMENTAL PROCEDURES

**Materials**—The human PC cell lines LNCaP, DU145, ALVA41, and PC3 were maintained as described previously (18). HEK293 and COS7 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 10 units/liter penicillin, and 10  $\mu$ g/ml streptomycin in 75-cm<sup>2</sup> flasks in a humidified 5% CO<sub>2</sub> incubator at 37 °C. The following items were obtained commercially: 5 $\alpha$ -dihydrotestosterone (DHT; Sigma); IGF1 (R&D Systems, Minneapolis, MN), insulin (Sigma); anti-AR N-terminal (N-20) antibody (Santa Cruz Biotechnology, Santa Cruz, CA); anti-FLAG M2 monoclonal antibody; and anti-FKHR (Foxo1) monoclonal antibody (Sigma).

The firefly luciferase reporter plasmids pGL3-MMTV, pPSA-LUC, GRE-Luc, and pERE2-tk109-LUC, as well as expression vectors for human AR (pCMV-hAR), estrogen receptor (ER) (pSG5-Er $\alpha$  and pSG5-Er $\beta$ ), GR $\alpha$  (pSG5-GR $\alpha$ ), PR (pSG5-PRA and pSG5-PRB), an AR-EGFP chimera (pCMV-AR-GFP), and expression vectors for FLAG-mFoxo1 (mouse) and FLAG-mFoxo1-3A (T24A, S253A, and S316A) chimeras were described previously (18–21). Full-length cDNAs encoding wild-type and mutant mFoxo1 were subcloned in-frame into pEYFP-C2 (Clontech) to generate EYFP-Foxo1 fusion vectors.

PRL-SV40, pG5-Luc, pBIND, and act expression vectors were obtained from Promega (Madison, WI). A full-length cDNA encoding human phosphatase and tensin homolog (PTEN) (mutated in multiple advanced cancers 1) (GenBank<sup>TM</sup> accession number NM\_000314) was obtained from OriGene Technologies, Inc. (Rockville, MD). A full-length cDNA encoding wild-type mFoxo1 was inserted in-frame into the act vector to generate a pACT-Foxo1 chimera. Expression vectors for pBIND-AR-N-(1–660) and pBIND-AR-C-(615–919) chimeras were constructed previously (18).

**Relative Luciferase Reporter Assays and Transfection**—Relative luciferase reporter assays were performed as described previously (22). Transfections were carried out using FuGENE 6 or FuGENE HD (Roche Applied Science). Stable clones expressing modest amounts of FLAG-Foxo1 or FLAG were established using 600  $\mu$ g/ml G418 sulfate.

**Cell Proliferation Assays**—The proliferation of LNCaP cells stably expressing either FLAG-Foxo1 or the control FLAG tag was determined using a CellTiter 96<sup>®</sup> nonradioactive cell proliferation assay kit (Promega) according to the manufacturer's instructions.

**Coimmunoprecipitation, Western Blotting, Mammalian Two-hybrid Assays, and Modified Mammalian One-hybrid Assays**—Coimmunoprecipitation, Western blotting, mammalian two-hybrid assays, and modified mammalian one-hybrid assays were performed essentially as described previously (23).

**Living Cell Laser Confocal Fluorescence Microscopy Assays**—Living cell laser confocal fluorescence microscopy assays were performed essentially as described previously (22). Colocalization and line scan analyses were carried out using the LSM software (version 3.0).

**Chromatin Immunoprecipitation (ChIP) Assays**—ChIP assays were performed essentially as described previously (24). An anti-AR N-20 antibody and anti-FLAG M2 monoclonal antibodies were applied. Primer information is available upon request.


**Real Time PCR**—Various transcripts in proper medium-treated cells were analyzed by real time PCR using a LightCycler as described previously (25, 26). Primer information for each target transcript is available upon request.

**PSA Measurements**—Secretion of human PSA protein into the cell culture medium was measured using an enzyme immunoassay (EIA) at SRL Inc. (Tokyo, Japan).

**Statistical Analysis**—Data were expressed as means  $\pm$  S.D. and evaluated by Student's two-tailed *t* test or ANOVA, followed by post hoc comparisons with Fisher's protected least significant difference test. Values of *p* < 0.05 were considered statistically significant.

### RESULTS

**Foxo1 Represses Ligand-induced AR Transactivation and Delays LNCaP Cell Proliferation**—Initially, the effects of Foxo1 on the transactivation induced by ligand-bound AR were investigated using relative luciferase activity assays. COS7 cells were cotransfected with pCMV-hAR and an artificial luciferase reporter for AR (pGL3-MMTV) together with increasing doses of a Foxo1 expression vector. As shown in Fig. 1*a*, Foxo1 inhibited agonist-induced transcription from the MMTV promoter in a dose-dependent manner. Similarly, the transactivation of endogenous AR monitored by the MMTV promoter in LNCaP human PC cells was suppressed by Foxo1 in a dose-dependent manner (supplemental Fig. 1*a*). Foxo1 also inhibited liganded AR-mediated expression of the promoter of a native AR target gene, PSA, in both COS7 (supplemental Fig. 1*b*) and DU145 (supplemental Fig. 1*c*) human PC cells. Thus, the inhibitory effect of Foxo1 on AR, either exogenous or endogenous, is not limited to one cell line and/or promoter. Endogenous Foxo1 mRNA was readily detectable by RT-PCR in all four PC cell



**FIGURE 1. Foxo1 represses ligand-induced AR transactivation and delays LNCaP cell proliferation.** *a*, COS7 cells growing in 24-well plates were transiently cotransfected with a DNA mixture consisting of 300 ng of pGL3-MMTV, 5 ng of pRL-CMV, 30 ng of pCMV-hAR, and increasing amounts (0–120 ng/ml) of FLAG-Foxo1. The empty pcDNA-FLAG vector was cotransfected to equalize the total amount of DNA (in terms of the molar amount) and control for artifacts of the vector DNA. The cells were then treated with 10<sup>-8</sup> M DHT or the solvent (ethanol) dissolved in serum-free medium for 24 h, before being analyzed by luciferase assays. *b* and *c*, LNCaP cells stably expressing FLAG-Foxo1 or the control FLAG tag were exposed to increasing concentrations of DHT as indicated. Endogenous expression of PSA mRNA (*b*) and PSA protein secreted into the culture medium (*c*) were assayed by real time PCR and EIA, respectively. *d*, LNCaP cells stably expressing either FLAG-Foxo1 or the control FLAG tag were grown in the presence of 10<sup>-8</sup> M DHT or the solvent (ethanol), and cell proliferation was dynamically evaluated using a CellTiter 96<sup>®</sup> nonradioactive cell proliferation assay kit. Data are presented as the mean  $\pm$  S.D. (*a*, *c*, and *d*) or mean  $\pm$  S.E. (*b*). Letters above the bars show statistical groups (ANOVA,  $p < 0.05$ ). RLA, relative luciferase activity.

lines, namely ALVA41, DU145, LNCaP, and PC3 cells, with DU145 and LNCaP cells showing 2-fold higher expression levels than PC3 and ALVA41 cells (supplemental Fig. 1*d*).

To further explore the relevance of the inhibitory effects of Foxo1 on AR observed in the promoter assays, the androgen-mediated endogenous PSA expression levels were studied in LNCaP cells stably expressing either FLAG-Foxo1 or the control FLAG tag. As shown in Fig. 1, *b* and *c*, DHT-stimulated PSA expression, which was dose-dependent in terms of both the mRNA level (assayed by real time PCR) and the amount of protein secreted into the medium (quantified by EIA), was significantly lower in cells overexpressing Foxo1, indicating that Foxo1 down-regulates the expressions of endogenous androgen-responsive genes. Lentivirus was applied as an additional method for overexpressing Foxo1 in LNCaP cells, and similar results were obtained (supplemental Fig. 1*e*).


Foxo1 also acted on other steroid hormone receptors (supplemental Fig. 2). Specifically, it enhanced the transcription mediated by liganded PR-A, PR-B, and GR $\alpha$ , exhibited no dramatic effect on ER $\alpha$ , but suppressed ER $\beta$  function in a similar manner to that observed for AR. Thus, the inhibitory effects are relatively specific for AR and ER $\beta$ .

LNCaP cells are typical androgen-responsive PC cells, and their proliferation is largely dependent on the availability of androgen as well as functional AR. To study the effects of Foxo1 on LNCaP cell growth, the two cell lines stably expressing either FLAG-Foxo1 or the control FLAG tag were grown in medium containing charcoal-stripped serum supplemented with either DHT (10<sup>-8</sup> M) or vehicle (ethanol), and a time course experiment was performed. Among the cells grown in the presence of DHT, the number of FLAG-Foxo1-expressing cells was decreased compared with control cells, even after 1 day of treatment, and then continued to decrease in a time-dependent manner (Fig. 1*d*). The basal proliferation in the presence of ethanol was also reduced to some extent in the stable FLAG-Foxo1-expressing cells, but more prominent inhibition was observed in cells treated with DHT. Thus, Foxo1 overexpression reduced the proliferation of LNCaP cells.

**IGF1 Ameliorates Foxo1 Suppression over AR Transactivation**—Foxo1 protein is a target of Akt kinase and negatively regulated by phosphorylation in an insulin- and/or IGF1-dependent manner, with resultant nuclear exportation

and cytoplasmic sequestration. Therefore, either IGF1 or insulin is expected to attenuate the inhibitory effects of Foxo1 on AR. Initially, we observed that a constitutively active mutant, Foxo1-3A (nonphosphorylatable mutant with all three Akt target residues mutated to alanine, specifically T24A, S253A, and S316A), was more potent than Foxo1 at suppressing DHT-induced AR transactivation (Fig. 2) in LNCaP cells, in which the impaired PI3K/Akt signaling was rescued by cotransfection of PTEN (LNCaP cells lack functional PTEN, and their Akt is constitutively active (27, 28)). In these PTEN-expressing LNCaP cells, IGF1 significantly augmented liganded AR-mediated PSA promoter activities. Of importance, the IGF1-augmented DHT-induced AR transactivation was sharply suppressed by Foxo1-3A but not by wild-type Foxo1. In other words, IGF1 abolished the suppression of liganded AR by wild-type Foxo1 but not that mediated by the Akt-nonphosphorylatable Foxo1 mutant. The rescue by IGF1 was dose-dependent (supplemental Fig. 3*a*) and also found in DU145 cells, which contain intact PTEN and PI3K/Akt signaling (supplemental Fig. 3*c*). Intriguingly, insulin, another PI3K/Akt stimulator, also enhanced the DHT-induced AR transactivation in the PTEN-expressing

## Foxo1 Represses AR




**FIGURE 2. IGF1 ameliorates Foxo1-suppressed AR transactivation.** LNCaP cells growing in 24-well plates were cotransfected with 100 ng of FLAG-Foxo1, FLAG-Foxo1-3A (Akt-nonphosphorylatable constitutively active mutant), or an equimolar amount of pcDNA-FLAG together with 400 ng of PSA-Luc, 5 ng of pRL-CMV, 40 ng of PTEN, and 40 ng of pCMV-hAR. At 48 h post-transfection, the cells were exposed to  $10^{-8}$  M DHT and/or 100 ng/ml IGF1 in serum-free medium for 24 h, before being lysed and analyzed by luciferase assays. Letters above the bars show statistical groups (ANOVA,  $p < 0.05$ ). The ascending order of the groups is as follows: F, A, C, G, E, H, B, and D. RLA, relative luciferase activity.

LNCaP cells in a concentration-dependent manner, albeit less potently (supplemental Fig. 3b).

To exclude the possibility that Foxo1 inhibits AR transactivation by decreasing the protein level of the receptor, the AR protein level was examined by immunoblotting under the same conditions used for the reporter assays. As shown in supplemental Fig. 4, *a-c*, cotransfection of Foxo1 with AR into LNCaP cells did not alter the AR protein level in either the presence or absence of DHT. Similarly, the AR mRNA expression level in lentiviral Foxo1-infected LNCaP cells was not significantly altered (supplemental Fig. 4*d*). Hence, these data indicate that Foxo1 suppresses the specific activity of the receptor.

**Physical Interaction between Foxo1 and AR**—Next, we examined whether there is a direct physical interaction between AR and Foxo1 by using coimmunoprecipitation assays. LNCaP cells cotransfected with FLAG-Foxo1 and pCMV-hAR together with PTEN and grown in serum-free medium were treated with IGF1, insulin, or PBS in combination with DHT or ethanol. As shown in Fig. 3*a* (upper panel), FLAG-Foxo1 bands were detected in anti-AR antibody-precipitated immune complexes from cells treated with DHT (lanes 6–8), whereas a very weak signal was detected in ethanol-treated cells (lane 2), suggesting that Foxo1 and AR interact directly, and their interaction is significantly enhanced by the AR ligand. The presence of IGF1 or insulin did not abolish the interaction (Fig. 3*a* (upper panel), lanes 7 and 8), although both molecules appeared to reduce the amount of Foxo1 protein interacting with liganded AR. In contrast, no Foxo1 signal was detectable in normal rabbit IgG-precipitated immune complexes from cells treated with either ethanol (Fig. 3*a* (upper panel), lane 1) or DHT (lane 5), indicating the specificity of the Foxo1-AR interaction. Using PTEN-expressing LNCaP cells, we further verified that endogenous AR and Foxo1 interacted in an androgen-dependent manner (supplemental Fig. 5), suggesting that the observed interaction is physiologically meaningful and that Foxo1 may repress liganded activated AR via a direct protein-protein interaction.



**FIGURE 3. Physical interaction between Foxo1 and AR.** *a*, coimmunoprecipitation of AR with Foxo1. LNCaP cells transfected with PTEN, pCMV-hAR, and pcDNA-FLAG-Foxo1 or the control empty vector pcDNA-FLAG were treated with PBS, IGF1 (100 ng/ml), or insulin (10  $\mu$ g/ml) in combination with DHT ( $10^{-8}$  M) or ethanol as indicated. Aliquots (1000  $\mu$ g) of whole cell extracts were incubated with 5  $\mu$ g of rabbit anti-AR (N-20) antibody or control normal rabbit IgG together with 50  $\mu$ l of protein A beads, and the presence of FLAG-Foxo1 in the immunoprecipitates (IP) was detected by immunoblotting (IB) with an anti-Foxo1 mouse monoclonal antibody. Immunoprecipitation of AR by the anti-AR (N-20) antibody was validated by using an anti-AR antibody obtained from Cell Signaling (catalog number 3202). The presence of AR and Foxo1 in the input cell lysate samples were confirmed. *b*, modified one-hybrid assays. COS7 cells were cotransfected with 50 ng of vectors for Foxo1 (pcDNA-FLAG-Foxo1), VP16-Foxo1 fusion protein (pACT-Foxo1), or both together with 300 ng of pGL3-MMTV, 5 ng of pRL-CMV, and 50 ng of pCMV-hAR and subsequently treated with  $10^{-8}$  M DHT,  $10^{-6}$  M casodex,  $10^{-6}$  M hydroxylflutamide, or the solvent (ethanol), respectively, for 24 h, before being analyzed by luciferase assays. Note that the DHT-induced AR transactivation is inhibited by Foxo1 but enhanced by VP16-Foxo1. The ascending order of the groups is A, F, G, C, B, E, and D. *c* and *d*, the C terminus of AR mediates the interaction with Foxo1. Mammalian two-hybrid assays were carried out to test for an *in vivo* interaction between AR and Foxo1. COS7 cells were cotransfected with a DNA mixture consisting of 100 ng of pG5-LUC, 1.5 ng of pRL-CMV, and 75 ng of pACT-Foxo1 together with 25 ng of pBIND-AR-N (*c*) or equimolar amounts of pBIND-AR-C (*d*). After the transfection, the cells were treated with  $10^{-8}$  M DHT or ethanol. Parallel experiments in which pACT-Foxo1 was replaced with pACT-Foxo1-R (Foxo1 fused with VP16 in the reverse orientation) were carried out as controls. Letters above the bars show statistical groups (ANOVA,  $p < 0.05$ ). RLA, relative luciferase activity.

The interaction was further confirmed by modified mammalian one-hybrid assays (29). COS7 cells were cotransfected with an MMTV reporter and AR together with wild-type Foxo1,

pACT-Foxo1, or both, and then treated with DHT or two antiandrogens, namely hydroxyflutamide and casodex. As shown in Fig. 3*b*, FLAG-Foxo1 inhibited DHT-induced AR transactivation as expected. However, pACT-Foxo1 (with a viral VP16 activation domain fused to the Foxo1 N terminus) enhanced the liganded AR function, and the coexistence of FLAG-Foxo1 and pACT-Foxo1 neutralized the luciferase activity. Thus, although Foxo1 was suppressive toward AR, VP16-Foxo1 became an artificial coactivator for AR, and this remarkable shift strongly suggests that there is a direct interaction between AR and Foxo1. Interestingly, the antiandrogens casodex and hydroxyflutamide did not produce the same phenomenon, suggesting that only an agonist can induce the interaction.

Further clarification of the individual domains of AR responsible for the interaction with Foxo1 was carried out by mammalian two-hybrid assays, in which the AR N terminus (amino acids 1–660) and C terminus (amino acids 615–919) were individually fused to the DNA-binding domain of GAL4 to produce pBIND-AR-N and pBIND-AR-C, respectively. As a control, the full-length Foxo1 cDNA was fused to the VP16 activation domain in either the forward (pACT-Foxo1-F) or reverse orientation (pACT-Foxo1-R). In comparison with pACT-Foxo1-R, pACT-Foxo1-F did not alter the activity of the pG5-LUC reporter coexpression with pBIND-AR-N in either the presence or absence of the ligand, suggesting a lack of interaction between the AR N terminus and Foxo1 (Fig. 3*c*). In the case of pBIND-AR-C coexpression, pACT-Foxo1-F, but not pACT-Foxo1-R, significantly stimulated the reporter in the presence of DHT (Fig. 3*d*). These data indicate that the AR C terminus interacts with Foxo1 in a hormone-dependent manner.

**Subcellular Interactions between Foxo1 and AR in Living Cells**—The intracellular distribution of EYFP-Foxo1 in living COS7 cells was visualized using laser confocal scanning microscopy. Consistent with previous observations (17), EYFP-Foxo1 in serum-starved COS7 cells was predominantly located in the nucleus in a homogeneous manner, with relatively weak diffuse fluorescence also visible in the cytoplasm (Fig. 4*a*). However, the nuclear accumulation of Foxo1 varied among the examined cells (supplemental Fig. 6, *a–c*). This variation was presumably because of differing IGF1/insulin signaling tones among the different cells, because challenge with IGF1 caused 100% of the EYFP-Foxo1-expressing cells to show complete cytoplasmic fluorescence (Fig. 4*b*). As expected, EGFP-AR predominantly showed diffuse fluorescence in the cytosol with very weak nuclear fluorescence in the absence of the ligand (Fig. 4*c*), whereas DHT induced complete nuclear translocation and typical subnuclear foci formation (Fig. 4*d*). When EYFP-Foxo1 and EGFP-AR were coexpressed, both proteins showed their original distribution patterns in cells treated with the control solvents (IGF1–/DHT–; Fig. 4*f*). Among the cells treated with DHT alone (IGF1–/DHT–; Fig. 4*g*), the distribution of EYFP-Foxo1 remained almost unchanged, whereas EGFP-AR exhibited incomplete nuclear translocation and significantly impaired subnuclear compartmentalization (foci formation) and was diffuse in both the nucleus and cytoplasm. Although a subgroup of cells showed relatively complete nuclear translocation, their foci formation was apparently impaired (supplemental Fig. 6*d*). In cells treated with IGF1 alone (IGF1+

DHT–; Fig. 4*i*), EYFP-Foxo1 was completely exported to the cytoplasm, whereas EGFP-AR maintained its original distribution, namely predominant diffuse cytoplasmic localization with weak nuclear fluorescence. In comparison with IGF1–/DHT+ cells (Fig. 4*g*), EGFP-AR in cells treated with both ligands (IGF1+/DHT+; Fig. 4*j*) showed more complete nuclear translocation and, importantly, also exhibited significantly improved subnuclear compartmentalization.

To quantitatively evaluate the effects of IGF1/Foxo1 on the subnuclear distribution of liganded AR, the intranuclear distribution patterns of EGFP-AR in the cell populations, shown representatively in Fig. 4, *d, g*, and *j*, were subjected to line scan analyses using the LSM software as described previously (22). In Fig. 4, *e, h*, and *k* show the line scan data of *d, g*, and *j*, respectively. In total, 20 cells from each group were subjected to the line scan analyses. The fluorescence intensity of the cells in Fig. 4*d* was quite heterogeneous (heterogeneity index (HI) =  $53.12 \pm 10.53$ ), whereas cotransfection of Foxo1 (cells in Fig. 4*g*) decreased the HI to  $17.83 \pm 9.46$ , indicating that the AR distribution in these cells was quite constant. The HI value recovered to  $35.16 \pm 18.89$  in cells further treated with IGF1 (cells in Fig. 4*j*), suggesting that the Foxo1-inhibited subnuclear reorganization of liganded AR was partially rescued by IGF1.


3T3-L1 cells contain a relatively high quantity of endogenous AR, which undergoes typical subnuclear reorganization and forms fine foci in the presence of DHT (23). To address whether Foxo1 also suppresses the foci formation of endogenous AR, EYFP-Foxo1 was expressed in 3T3-L1 cells, and the endogenous AR distributions in the presence and absence of DHT were studied by immunofluorescence staining. As shown in supplemental Fig. 7, DHT-induced AR foci were significantly suppressed by Foxo1 overexpression. Specifically, the HI of liganded nuclear AR was  $66.26 \pm 15.77$  ( $n = 20$ ) in the absence of Foxo1 but reduced to  $38.25 \pm 8.91$  ( $n = 20$ ,  $p < 0.01$ ) by Foxo1.

The distribution of EYFP-Foxo1 in cells coexpressing EGFP-AR and treated with both ligands (IGF1+/DHT+) was striking in that a substantial amount of Foxo1 remained in the nucleus (Fig. 4*j* and supplemental Fig. 6*e*). This distribution is in great contrast to that in the cells in Fig. 4, *b* and *i*, where IGF1 induced complete nuclear export of Foxo1 in all cells. These observations suggest that liganded AR sequestered part of the Foxo1 in the nucleus, even in the presence of IGF1. Furthermore, the nuclear Foxo1 in these cells was heterogeneous and colocalized with ligand-bound AR (Fig. 4*j* and supplemental Fig. 6*e*), suggesting an interaction between the two proteins.

In contrast to EYFP-Foxo1, EYFP-Foxo1-3A resided in the nucleus in a reticular manner regardless of the IGF1 availability. Furthermore, it disrupted DHT-induced AR foci formation, and importantly, the disruption was not rescued by IGF1 (supplemental Fig. 8).

**Interaction of Foxo1 and AR within the Human PSA Promoter**—Next, ChIP assays were carried out to determine whether Foxo1 and AR associate with the chromatin of an AR target gene promoter *in vivo*. LNCaP cells cotransfected with pcDNA-FLAG-Foxo1 and pCMV-hAR were subjected to serum starvation and challenged with IGF1, insulin, or PBS as a control in the presence of DHT or the solvent (ethanol).

**Foxo1 Represses AR**



Genomic DNA corresponding to the androgen-response elements ARE I/II and ARE III, which are located in the promoter and enhancer of the *PSA* gene, respectively, was remarkably enriched in a DHT-dependent manner, as evaluated using an anti-FLAG antibody (Fig. 5*b*). Weak bands were detectable in the absence of any ligand, whereas treatment of the cells with IGF1 or insulin either abolished or significantly reduced the occupancy of the DNA by Foxo1, regardless of the presence or absence of DHT. There was very weak Foxo1 occupancy of the DNA in a region between the enhancer and the promoter, but no enrichment was detected in the presence of DHT, thus demonstrating specificity (Fig. 5*b*). Again, the weak bands vanished in the presence of IGF1 or insulin. The association of Foxo1 with the chromatinized *PSA* promoter was specific, because DNA from the *GAPDH* gene was not precipitated (Fig. 5*b*). Thus, agonist-bound AR induces specific associations of Foxo1 with chromatin AREs on the *PSA* promoter, demonstrating that Foxo1 and AR form a ligand-dependent complex on chromatin. Furthermore, IGF1 and insulin are able to remove Foxo1 from chromatinized DNA.

The ChIP assays further revealed that Foxo1 interfered with ligand-induced recruitment of AR to the *PSA* promoter in LNCaP cells. The cells were transfected with pCMV-hAR together with pcDNA-FLAG-Foxo1-3A or pcDNA-FLAG and treated with the ligand as described above. Chromatin-transcription factor complexes were precipitated with an anti-AR antibody and combined with real time PCR analysis to quantify the relative number of immunoprecipitated DNA copies to the input control for each sample as described previously (24). Small amounts of the DNA segments corresponding to *PSA* ARE I/II and ARE III were detected in the absence of DHT, and DHT induced significant enrichment of these amounts (Fig. 5*c*). IGF1 or insulin increased the AR-DNA interaction under each circumstance (presence or absence of DHT; Fig. 5*c*). Overexpression of the nonphosphorylatable Foxo1-3A significantly reduced the relative copy numbers of *PSA* promoter DNA at both positions, especially in the presence of DHT (Fig. 5*c*), suggesting that the association between the *PSA* promoter and liganded AR was impaired. Furthermore, Foxo1-3A also substantially abolished the responsiveness to IGF1 and insulin (Fig. 5*c*), indicating that intact and phosphorylatable Foxo1 is vital for IGF1 or insulin to enhance the liganded AR-DNA interaction.

**Activation of AR Stimulates IGF1R Expression in LNCaP Cells**—We further found that IGF1R expression was up-regulated in LNCaP cells in the presence of DHT. As shown in Fig.

6*a*, DHT treatment for 24 h dose-dependently increased the IGF1R mRNA levels in serum-starved LNCaP cells, and  $10^{-8}$  M DHT boosted the mRNA level by 17-fold. This stimulation of IGF1R was relatively specific, because comparable concentrations of DHT did not increase the levels of epidermal growth factor receptor (supplemental Fig. 9*a*) and Foxo1 mRNAs (supplemental Fig. 9*b*). An autoregulation process may occur, because the up-regulated IGF1R is expected to enhance IGF1-PI3K-Akt signaling, thereby resulting in a further gain-of-function of AR via phosphorylation of the repressive Foxo1.

## DISCUSSION

**Foxo1 Suppression and IGF1-related Mechanism of Refractory PC**—IGF1 is capable of reactivating AR in low or absent androgen environments and therefore represents one of the suggested multiple mechanisms by which PC cells progress to the androgen-insensitive stage (7). However, the mechanisms by which IGF1 and other growth factors regulate AR-mediated transcription in PC cells remain unclear.

IGF1, via binding to its receptor IGF1R, activates intracellular signaling pathways that favor proliferation and cell survival. One of the most important pathways that becomes activated is the PI3K/Akt pathway (30), because activation of this pathway by IGF1, as well as other molecules, has been implicated in PC. Specifically, increases in IGF1R expression (11, 31, 32) and loss of the tumor suppressor gene *PTEN* (27, 28) elicit increased activity of the PI3K/Akt pathway and greatly contribute to tumor progression of PC.


Foxo1, which is endogenously expressed in PC cells, is functionally inhibited by phosphorylation at Ser-253, Ser-316, and Thr-24 in response to IGF1 or insulin through PI3K/Akt kinase (17). Overexpression of Foxo1 in PC cells leads to apoptosis (33). Our present results have revealed that Foxo1 directly interacts with and suppresses the transactivation of AR, whereas IGF1 signaling ameliorates this suppression and results in AR gain-of-function. Thus, considering the reported mechanism that  $\beta$ -catenin may mediate the stimulatory effect of IGF1 signaling on AR (34), Foxo1 may represent an alternative explanation.

Because insulin induces PI3K-Akt signaling and the resultant modification of Foxo1 (17), similar to IGF1, and also enhances AR transactivation in *PTEN*-expressing LNCaP cells, it is of great value to further elucidate whether insulin signaling enhances AR function via a similar mechanism. Regarding this point, it is noteworthy that the syndrome of insulin resistance, which is characterized by an increased insulin level and abdom-

**FIGURE 4. Subcellular interaction between Foxo1 and AR in living COS7 cells.** The expressions of chimeric fluorescent proteins were observed in living COS7 cells using a Zeiss LSM 510 META laser confocal microscope as described under "Experimental Procedures." *a* and *b*, COS7 cells were transfected with 0.5  $\mu$ g/dish of EYFP-Foxo1 and then treated with PBS (*a*) or 100 ng/ml IGF1 (*b*). *c* and *d*, COS7 cells expressing EGFP-AR were exposed to ethanol (*c*) or  $10^{-8}$  M DHT (*d*), respectively. *f*, *g*, *i*, and *j*, COS7 cells coexpressing EGFP-AR and EYFP-Foxo1 were exposed to DHT and/or IGF1 as indicated in the individual panels. The fluorescence signals for green fluorescent protein (GFP) and yellow fluorescent protein (YFP) and the merged images are shown separately. *e*, *h*, and *k*, line scan analyses. A straight line was drawn through the target cell, and the fluorescence intensities along the line were recorded. The mean and S.D. values of the fluorescence intensity signals for the segment of interest (nucleus, avoiding the nucleolus) were calculated. The heterogeneity of the fluorescence intensity along the segment of interest was evaluated by the parameter of the HI, which was calculated using the following formula:  $HI = 100 \times S.D./mean$ . A fluorescence intensity fluctuation graph, which clearly demonstrated the heterogeneity, was then created by plotting the intensity against the distance along the line. The lines obtained by line scan analyses are shown for representative cells. The fluorescence intensity fluctuation graphs of the representative cells are shown in *e*, *h*, and *k* and relate to the cells in *d*, *g*, and *j*, respectively. The x axis represents the distance along each line, whereas the y axis shows the fluorescence intensity. The bar within each graph marks the segment of the line for which the HI analysis was performed, and the corresponding intensity and HI values are indicated at the top of each graph. Scale bars, 10  $\mu$ m.



## Foxo1 Represses AR



**FIGURE 5. Interaction of Foxo1 and AR within the human PSA promoter.** *a*, schematic diagram of the human PSA gene promoter region. The positions of the putative AREs are indicated, and the transcription start site is designated 1. Pairs of arrows indicate the PCR-amplified regions. *b*, occupancy of the PSA gene-regulatory regions by Foxo1. Soluble chromatin was prepared from FLAG-Foxo1-expressing LNCaP cells treated with the indicated ligands ( $10^{-8}$  M DHT; 100 ng/ml IGF1; 10  $\mu$ g/ml insulin) for 30 min and then immunoprecipitated with an anti-FLAG antibody or normal mouse IgG as a control. Enrichment of ARE-containing DNA sequences in the immunoprecipitated DNA pool, indicating association of Foxo1 with the PSA promoter within intact chromatin, was visualized by PCR. The lower panels show the PCR-amplified PSA promoter bands from the input controls. *c*, effects of IGF1/insulin and Foxo1 on the occupancy of the PSA gene-regulatory regions by AR. Additional real time PCR was performed to quantify the amount of immunoprecipitated PSA promoter DNA copy numbers from cells under various treatments relative to their corresponding input controls.

inal obesity, is also associated with an increased incidence of PC and development of a more aggressive form of the disease (14, 15), although the mechanism remains unclear.


Nevertheless, the association between the risk of PC and the serum insulin level remains a controversial topic (35). There is even a lack of consensus over the association between the circulating level of IGF1 and the PC risk (30). With regard to this concern, our present results suggest that, in contrast to systemic circulating growth factors, there is also potential importance for the local bioavailability of growth factors and their cross-talk with hormones. Ligand-bound AR, which is functionally enhanced by IGF1-PI3K-Akt signaling-mediated disso-

ciation of the repressor Foxo1, in turn stimulates the expression of IGF1R and presumably results in increased tension of IGF1 signaling, thereby leading to further functional augmentation of the receptor itself. Consistently, androgen withdrawal leads to a decrease in PI3K-Akt signaling (36, 37). Thus, as depicted in Fig. 6*b*, a mutually stimulatory feedback circuit (androgen-AR increases IGF1 signaling tension, whereas IGF1 signaling enhances AR transactivation), which works in an autocrine/intracrine manner in the local cellular environment of PC, may play important roles in up-regulation of AR function and PC progression.

**AR Subnuclear Compartmentalization and Transactivation**—Ligand-induced subnuclear compartmentalization (foci formation) is closely correlated with the transcriptional activation function of nuclear receptors (19–20, 22). DHT induces 250–400 fine and well separated subnuclear AR foci (19, 20), and the process is accompanied by the recruitment of coactivators such as SRC-1, TIF2, and CBP (20). AR bound to antiandrogens, such as hydroxyflutamide, does not form any foci (19), and cofactors that repress AR function readily disrupt DHT-induced foci formation by the receptor (18, 38). Our recent study further proved that the intranuclear complete/distinct foci formation of an agonist-bound steroid hormone receptor is an indicator of its transcriptional activation status (23).

Regarding this point, Foxo1 is able to disrupt AR nuclear translocation, and more importantly, the subnuclear foci formation induced

by DHT is mechanistically significant. Although the mechanism remains to be elucidated, it can be speculated that Foxo1 may compete with coactivators, such as CBP, which is essential for AR foci formation (20) and for interaction with the receptor, and thereby inhibit the formation of transcriptionally active complexes. Importantly, our quantitative study revealed that IGF1 can rescue, at least partially, the Foxo1-disrupted AR subnuclear compartmentalization but not the disruption caused by the Akt-nonphosphorylatable constitutively active mutant Foxo1-3A. Therefore, Foxo1 interferes with the subnuclear compartmentalization of ligand-bound AR, and this effect is regulated by IGF1-PI3K-Akt signaling.



**FIGURE 6. Stimulatory feedback circuit between IGF1/insulin signaling and AR transactivation.** *a*, DHT up-regulates IGF1R mRNA expression. LNCaP cells were serum-starved and then incubated with increasing concentrations of DHT for 24 h. Next, total RNA was extracted and reverse-transcribed into cDNAs, before the IGF1R mRNA expression levels were analyzed by real time PCR as described under "Experimental Procedures." The relative mRNA amounts were normalized to the corresponding abundance of GAPDH mRNA. Triplicate results are expressed as the mean  $\pm$  S.D. Letters above the bars show statistical groups (ANOVA,  $p < 0.05$ ). *b*, proposed model for the cross-talk between IGF1/insulin signaling and AR. The local bioavailability of IGF1 (and/or insulin), which is probably abnormally high in PC, can be delivered from remote sites of production through the circulation or produced locally. Following ligand binding to IGF1R or insulin receptor, the tyrosine activity is activated, and this stimulates signaling pathways through intracellular networks that regulate cell proliferation and cell survival. One of the key downstream networks is the PI3K-Akt system. Akt, or a similar phosphatidylinositol 3,4,5-trisphosphate (*PIP3*)-dependent kinase, translocates to the nucleus and phosphorylates Ser-253, Ser-316, and Thr-24 of Foxo1. Phosphorylated Foxo1 is exported to the cytoplasm, where it has the potential to bind 14-3-3 protein and become retained in the cytoplasm. Foxo1 interacts with the C-terminal region of AR in the presence of a ligand (androgens such as DHT) and interferes with the ligand-induced subnuclear compartmentalization of AR, as well as the liganded receptor-target gene promoter interaction, thereby shutting down the AR transactivation. Modification of Foxo1 by the PI3K-Akt system, which is activated by IGF1 and/or insulin, weakens the Foxo1-AR interaction and ameliorates the inhibitory effects of Foxo1 on AR. Ligand-bound AR, in turn, stimulates the expression of IGF1R, resulting in enhanced IGF1 signaling tension. Moreover, liganded AR may also strengthen the net outcome of the IGF1-PI3K-Akt-Foxo1 axis by inducing biodegradation and/or direct functional inhibition of Foxo1, which results in further amelioration of Foxo1-related apoptosis of PC cells. These mutually inhibitory interactions between AR and Foxo1 functioning in the context of a positive feedback circuit between AR and IGF1 signaling and working in an autocrine/intracrine manner in the local cellular environment may play important roles in AR function modulation, prostate cell apoptosis, and also PC etiology and progression.

#### Foxo1-AR Interaction and Its Structural Basis and Regulation—

The direct interaction between Foxo1 and AR is ligand (DHT)-dependent and relies on the C terminus of the receptor, which is functionally ligand-dependent (20). Nuclear receptor cofactors bind to AR via peptide motifs called nuclear receptor boxes with a consensus sequence of LXXLL (L, leucine; X, any amino acid) (39). These boxes are present in the N terminus of Foxo1 and conserved from mice (<sup>459</sup>LKELL<sup>463</sup>) to humans (<sup>452</sup>LKELL<sup>466</sup>) (21). The role, if any, of this motif in mediating the Foxo1-AR interaction remains to be determined. The interaction is probably weakened, but not completely abolished, by IGF1, because IGF1 reduced the anti-AR antibody-immunoprecipitated Foxo1 levels and improved the Foxo1-disrupted AR subnuclear compartmentalization. Liganded AR also recruited Foxo1 to the chromatin of AR target gene promoters, where Foxo1, in turn, interfered with AR-DNA interactions, mirroring its disturbance of AR subnuclear compartmentalization. IGF1 or insulin, however, reduced the DNA occupancy by

Foxo1 but consistently enhanced that by AR. These IGF1/insulin regulations probably rely on Akt-mediated phosphorylation of Foxo1, because the Foxo1-3A-inhibited AR-DNA interaction as well as the AR foci formation was not recovered by IGF1/insulin. Thus, IGF1, and perhaps also insulin, appears able to regulate the Foxo1-AR interaction via PI3K/Akt phosphorylation of Foxo1. It is important to note that the effects of IGF1 and insulin on AR function are similar but not identical. IGF1 is generally more potent and efficient at enhancing AR transactivation, ameliorating the DHT-induced Foxo1-AR interaction and rescuing the Foxo1-interrupted AR subnuclear compartmentalization (data not shown), although the difference was not that obvious in the CHIP assays. This phenomenon is presumably because of differential phosphorylation patterns of Foxo1 in response to IGF1 and insulin signaling. Although both hormones bind to their cognate receptors and activate the PI3K-Akt kinase cascade, which phosphorylates Foxo1 at Thr-24, Ser-253, and Ser-316, previous studies on hepatocytes (17) revealed that the phosphorylation patterns differ. Although the signaling pathways triggered by IGF1R and insulin receptor both phosphorylate the Akt site at Ser-253, which is a prerequisite for phosphorylation of the other two potential Akt sites Thr-24 and Ser-316, Thr-24 is phosphorylated by an unknown kinase that is specifically induced by insulin receptor. This type of site-specific phosphorylation of Foxo1, and the corresponding profiles of kinases downstream of IGF1 and insulin receptor in the LNCaP cellular environment, may provide a potential explanation for the different effects of IGF1 and insulin on the Foxo1-AR interaction as well as AR function.

It is noteworthy that another group also investigated the Foxo1-AR interaction recently (40). Consistent with our data, full-length AR, as well as its C-terminal ligand-binding domain, was found to interact with Foxo1 in an androgen-dependent manner, although the authors also reported a ligand-independent interaction between the N-terminal A/B region of the receptor and Foxo1, which we did not observe in our mammalian two-hybrid assays. Through direct interactions, ligand-bound AR was found to be able to inhibit DNA binding, as well as the transactivation activity of Foxo1, and impair the ability of Foxo1 to induce prostate cell apoptosis and cell cycle arrest (40). Liganded AR is also reportedly able to induce Foxo1 protein proteolysis and therefore ameliorate Foxo1-related apoptosis of PC cells (41). These studies, in combination with our present findings, suggest that AR and Foxo1 are mutually suppressive in terms of functional regulation. Besides the above-mentioned IGF1R up-regulation, inhibition of Foxo1 provides an additional way in which liganded AR may enhance the IGF1/insulin-PI3K-Akt-Foxo1 axis. The mutual inhibition between Foxo1 and AR in the context of IGF1 signaling may play an important role in AR function and prostate cell apoptosis, as well as in PC etiology and progression (Fig. 6*b*).

Taken together, the present results have identified Foxo1, a molecule functionally inhibited by IGF1/insulin-PI3K-Akt signaling, as a novel corepressor for AR. The results further suggest that positive feedback between the growth factor and androgen in the local cellular environment may play important roles in the regulation of AR transactivation. These findings provide a new mechanism by which IGF1, and also potentially

## Foxo1 Represses AR

insulin, enhances AR transactivation and may shed new light on our understanding of the progression of PC to the androgen-insensitive stage. Pharmacological strategies that reduce IGF1/insulin signaling, in combination with antiandrogen therapies, are expected to have clinical benefits in fighting PC.

### REFERENCES

1. Brinkmann, A. O., and Trapman, J. (2004) *Adv. Pharmacol.* **47**, 317–341
2. Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. (2000) *CA-Cancer. J. Clin.* **50**, 7–33
3. Santos, A. F., Huang, H., and Tindall, D. J. (2004) *Steroids* **69**, 79–85
4. Zegarra-Moro, O. L., Schmidt, L. J., Huang, H., and Tindall, D. J. (2002) *Cancer Res.* **62**, 1008–1013
5. Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., and Sawyers, C. L. (2004) *Nat. Med.* **10**, 33–39
6. Buchanan, G., Irvine, R. A., Coetzee, G. A., and Tilley, W. D. (2001) *Cancer Metastasis Rev.* **20**, 207–223
7. Grossmann, M. E., Huang, H., and Tindall, D. J. (2001) *J. Natl. Cancer. Inst.* **93**, 1687–1697
8. Pollak, M., Beamer, W., and Zhang, J. C. (1998) *Cancer Metastasis Rev.* **17**, 383–390
9. Wolk, A., Mantzoros, C. S., Andersson, S. O., Bergstrom, R., Signorello, L. B., Lagiou, P., Adami, H. O., and Trichopoulos, D. (1998) *J. Natl. Cancer. Inst.* **90**, 911–915
10. Burfeind, P., Chernicky, C. L., Rininsland, F., and Ilan, J. (1996) *Proc. Natl. Acad. Sci. U. S. A.* **93**, 7263–7268
11. Nickerson, T., Chang, F., Lorimer, D., Smeekens, S. P., Sawyers, C. L., and Pollak, M. (2001) *Cancer Res.* **61**, 6276–6280
12. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., and Klocker, H. (1994) *Cancer Res.* **54**, 5474–5478
13. Orio, F., Jr., Terouanne, B., Georget, V., Lumbroso, S., Avances, C., Siatka, C., and Sultan, C. (2002) *Mol. Cell. Endocrinol.* **198**, 105–114
14. Amling, C. L. (2005) *Curr. Opin. Urol.* **15**, 167–171
15. Hsing, A. W., Gao, Y. T., Chua, S., Jr., Deng, J., and Stanczyk, F. Z. (2003) *J. Natl. Cancer Inst.* **95**, 67–71
16. Kops, G. J., and Burgering, B. M. (1999) *J. Mol. Med.* **77**, 656–665
17. Nakae, J., Barr, V., and Accili, D. (2000) *EMBO J.* **19**, 989–996
18. Chen, G., Nomura, M., Morinaga, H., Matsubara, E., Okabe, T., Goto, K., Yanase, T., Zheng, H., Lu, J., and Nawata, H. (2005) *J. Biol. Chem.* **280**, 36355–36363
19. Tomura, A., Goto, K., Morinaga, H., Nomura, M., Okabe, T., Yanase, T., Takayanagi, R., and Nawata, H. (2001) *J. Biol. Chem.* **276**, 28395–28401
20. Saitoh, M., Takayanagi, R., Goto, K., Fukamizu, A., Tomura, A., Yanase, T., and Nawata, H. (2002) *Mol. Endocrinol.* **16**, 694–706
21. Nakae, J., Cao, Y., Daitoku, H., Fukamizu, A., Ogawa, W., Yano, Y., and Hayashi, Y. (2006) *J. Clin. Investig.* **116**, 2473–2483
22. Fan, W., Yanase, T., Wu, Y., Kawate, H., Saitoh, M., Oba, K., Nomura, M., Okabe, T., Goto, K., Yanagisawa, J., Kato, S., Takayanagi, R., and Nawata, H. (2004) *Mol. Endocrinol.* **18**, 127–141
23. Wu, Y., Kawate, H., Ohnaka, K., Nawata, H., and Takayanagi, R. (2006) *Mol. Cell. Biol.* **26**, 6633–6655
24. Fan, W., Yanase, T., Morinaga, H., Mu, Y. M., Nomura, M., Okabe, T., Goto, K., Harada, N., and Nawata, H. (2005) *Endocrinology* **146**, 85–92
25. Fan, W., Yanase, T., Nomura, M., Okabe, T., Goto, K., Sato, T., Kawano, H., Kato, S., and Nawata, H. (2005) *Diabetes* **54**, 1000–1008
26. Pfaffl, M. W. (2001) *Nucleic Acids Res.* **29**, e45
27. Xin, L., Teitell, M. A., Lawson, D. A., Kwon, A., Mellinghoff, I. K., and Witte, O. N. (2006) *Proc. Natl. Acad. Sci. U. S. A.* **103**, 7789–7794
28. McMenamin, M. E., Soung, P., Perera, S., Kaplan, I., Loda, M., and Sellers, W. R. (1999) *Cancer Res.* **59**, 4291–4296
29. Liao, G., Chen, L. Y., Zhang, A., Godavathy, A., Xia, F., Ghosh, J. C., Li, H., and Chen, J. D. (2003) *J. Biol. Chem.* **278**, 5052–5061
30. Pollak, M. N., Schernhammer, E. S., and Hankinson, S. E. (2004) *Nat. Rev. Cancer* **4**, 505–518
31. Hellawell, G. O., Turner, G. D., Davies, D. R., Poulson, R., Brewster, S. F., and Macaulay, V. M. (2002) *Cancer Res.* **62**, 2942–2950
32. Grzmil, M., Hemmerlein, B., Thelen, P., Schweyer, S., and Burfeind, P. (2004) *J. Pathol.* **202**, 50–59
33. Modur, V., Nagarajan, R., Evers, B. M., and Milbrandt, J. (2002) *J. Biol. Chem.* **277**, 47928–47937
34. Verras, M., and Sun, Z. (2005) *Mol. Endocrinol.* **19**, 391–398
35. Stattin, P., and Kaaks, R. (2003) *J. Natl. Cancer Inst.* **95**, 1086–1087
36. Baron, S., Manin, M., Beaudoin, C., Leotoing, L., Communal, Y., Veysié, G., and Morel, L. (2004) *J. Biol. Chem.* **279**, 14579–14586
37. Castoria, G., Lombardi, M., Barone, M. V., Bilancio, A., Di Domenico, M., De Falco, A., Varricchio, L., Bottero, D., Nanayakkara, M., Migliaccio, A., and Auricchio, F. (2004) *Steroids* **69**, 517–522
38. Tao, R. H., Kawate, H., Wu, Y., Ohnaka, K., Ishizuka, M., Inoue, A., Hagiwara, H., and Takayanagi, R. (2006) *Mol. Cell. Endocrinol.* **247**, 150–165
39. McInerney, E. M., Rose, D. W., Flynn, S. E., Westin, S., Mullen, T. M., Krones, A., Inostroza, J., Torchia, J., Nolte, R. T., Assa-Munt, N., Milburn, M. V., Glass, C. K., and Rosenfeld, M. G. (1998) *Genes Dev.* **12**, 3357–3368
40. Li, P., Lee, H., Guo, S., Unterman, T. G., Jenster, G., and Bai, W. (2003) *Mol. Cell. Biol.* **23**, 104–118
41. Huang, H., Muddiman, D. C., and Tindall, D. J. (2004) *J. Biol. Chem.* **279**, 13866–13877

NOTE

## Changes in Serum Sex Hormone Profiles after Short-term Low-dose Administration of Dehydroepiandrosterone (DHEA) to Young and Elderly Persons

YOSHIHIKO YAMADA, HISAHIKO SEKIHARA, MASAO OMURA, TOSHIHIKO YANASE\*, RYOICHI TAKAYANAGI\*\*, TOMOATSU MUNE\*\*\*, KEIGO YASUDA\*\*\*, TATSUO ISHIZUKA#, HAJIME UESHIBA##, YUKITAKA MIYACHI###, TOMOYUKI IWASAKI, ATSUSHI NAKAJIMA### AND HAJIME NAWATA\*

*Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine*

*\*Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University*

*\*\*Department of Geriatric Medicine, Graduate School of Medical Sciences, Kyushu University*

*\*\*\*Department of Endocrinology, Diabetes and Rheumatology, Gifu University School of Medicine*

*#General Internal Medicine, Gifu University School of Medicine*

*##First Department of Internal Medicine, Toho University School of Medicine*

*###Department of Gastroenterology, Yokohama City University Graduate School of Medicine*

**Abstract.** In man, serum concentrations of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS) decrease with age after the twenties. For this reason, the decline in DHEA and DHEAS concentrations may be related to the development of some chronic diseases that are prevalent in the older age population. In this study, we evaluate the benefit and safety level of DHEA administration to men as a hormone replacement therapy. Twenty-two healthy Japanese males (age 26–63; mean  $\pm$  SD, 41.0  $\pm$  10.0 yrs.) received 25 mg DHEA once a day orally in the morning for two weeks. Serum concentrations of steroid hormones and cytokines were measured before and after the DHEA administration. Glucose tolerance and insulin resistance were also assessed before and after the DHEA administration using a 75 g oral glucose tolerance test and homeostasis model assessment (HOMA-R), respectively. Serum DHEA and DHEAS levels were significantly elevated after the DHEA administration for all ages of test subjects. In subjects who were older than 41 yrs. (older group) serum androstenedione and estradiol levels were elevated after the DHEA administration. Significant negative correlations were observed between the serum DHEA concentration and the serum concentration of fasting insulin, HOMA-R, leptin, and high-sensitivity C-reactive protein for all subjects. Daily administration of 25 mg DHEA increased the serum DHEA, DHEAS, androstenedione, and estradiol levels of the subjects of the older group to the same level as that of younger subjects.

**Key words:** Dehydroepiandrosterone (DHEA), Dehydroepiandrosterone sulfate (DHEAS), Androgen, Hormone replacement, Insulin resistance

(Endocrine Journal 54: 153–162, 2007)

**WHILE** it is known that there is an abundance of dehydroepiandrosterone (DHEA) and its sulfate conju-

gate (DHEAS) in the peripheral circulation in humans, their essential physiological roles still remain unclear. It is known that the secretion of DHEA increases with postnatal aging peaking in the twenties, and then decreases with age afterwards. Due to this type of dynamic change, the decline in DHEA and DHEAS secretion based on aging is compared to female menopause and expressed as adrenopause. The relationship of DHEA and DHEAS to symptoms of senility and geriatric disease has attracted much attention [1]. The re-

Received: September 26, 2005

Accepted: October 4, 2006

Correspondence to: Dr. Yoshihiko YAMADA, Department of Internal Medicine, Atami Hospital, International University of Health and Welfare, 13-1 Higashikaigan-cho, Atami, Shizuoka 413-0012, Japan

† Dr. Yukitaka Miyachi passed away on January 23, 2003.

port by Roth [2] shows that the lifespan of a person and the serum concentration of DHEA are related. There are also reports related to antiatherosclerotic [3–6], antidiabetic [7–9], antiinflammatory [10–12], and antiosteoporotic functions [13, 14], and we anticipate that DHEA has the so-called antisenility hormone function related to the aging phenomenon.

Hormone replacement therapy is a method for preventing or treating various chronic diseases associated with aging by replacing sex steroid hormones the levels of which decrease due to aging. In aging societies of various advanced countries, concern is on the rise regarding hormone replacement therapy. Although there are many studies underway on estrogen replacement therapy for postmenopausal women [15–18], the number of such studies on male hormone replacement therapy is not at the same level. In particular, there are only a few studies on the Japanese population [19, 20]. We conducted an investigation on a short-term and low-dose replacement therapy with DHEA on Japanese men and studied the influence on hormone dynamics, glucose tolerance, and insulin resistance.

## Materials and Methods

### Test subjects

Twenty-two normal healthy Japanese males (age 26–63; mean  $\pm$  SD, 41.0  $\pm$  10.0 yrs.) volunteered to be test subjects. Baseline characteristics of the 22 subjects are outlined in Table 1.

### Test design

An open-label test format was used. All subjects received 25 mg DHEA once a day orally in the morning for two weeks. The DHEA is a product of Advanced Brain Research Foundation, Inc. (Cambridge, MA) and was purchased from Gloria International Inc. (Tokyo, Japan). Blood sampling and a 75 g oral glucose tolerance test (75 g OGTT) were performed after 12 h of fasting on the day before and then after two weeks of the DHEA administration. Approval for this study was obtained from the Yokohama City University Hospital Ethical Committee.

### Measurement

Serum DHEA, DHEAS, androstenedione, estradiol

Table 1. Baseline Characteristics of 22 Subjects

Age (yr)	BMI (kg/m <sup>2</sup> )	FPG (mmol/l)	F-insulin (pmol/l)	HOMA-R	DHEA (nmol/l)	DHEAS ( $\mu$ mol/l)
63	23.3	6.2	159	7.26	11.1	2.5
41	24.1	5.6	29	1.18	26.7	5.6
49	23.0	5.2	27	1.02	12.8	3.2
40	24.1	5.4	61	2.44	9.0	5.2
35	22.8	5.7	169	7.15	6.6	5.0
35	23.9	4.5	35	1.17	18.7	3.4
30	21.9	5.5	57	2.32	26.7	15.6
27	18.9	5.2	84	3.25	24.6	13.0
30	33.1	5.8	134	5.78	8.7	11.3
44	21.2	4.9	23	0.82	10.4	3.0
51	24.8	6.6	60	2.91	20.5	5.5
43	22.9	5.2	42	1.60	22.9	7.6
46	22.0	5.4	32	1.27	20.8	12.0
31	20.0	5.8	35	1.51	55.5	8.0
26	21.0	5.1	35	1.33	11.8	6.2
26	27.3	5.5	41	1.66	23.9	7.4
49	22.9	5.5	45	1.85	9.0	3.1
49	21.5	5.1	74	2.79	28.8	4.3
42	23.0	5.2	19	0.71	17.7	7.2
51	21.8	5.0	25	0.97	34.3	9.1
51	22.9	5.0	37	1.38	15.3	8.7
43	20.4	4.4	58	1.89	31.2	12.6

BMI: Body mass index, FPG: Fasting plasma glucose, F-insulin: Fasting serum insulin

(E2), and free testosterone were measured using the solid phase radioimmunoassay (Diagnostic Products Corporation, CA, USA). Serum IGF-1 was measured using the solid phase radioimmunoassay (Daiichi Radioisotope Corporation, Tokyo, Japan). All of these measurements and complete blood count, liver function, renal function, electrolytes, lipids, glucose, and insulin measurements were performed in commercial laboratories (SRL, Inc., Tokyo, Japan).

Evaluation of insulin resistance was assessed with homeostasis model assessment (HOMA-R) and calculated using the following formula: fasting plasma glucose (mmol/L)  $\times$  fasting serum insulin (micro U/mL) divided by 25 [21]. We calculated the insulinogenic index, as the initial insulin secretion response index after glucose tolerance, using a previously described method [22, 23].

The serum concentration of leptin, adiponectin, and high-sensitivity C-reactive protein (hsCRP) was measured by radioimmunoassay (Cosmic Corporation, Tokyo, Japan), ELISA (Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan), and nephelometry (Dade Behring Inc., IL, USA), respectively. The plasma concentration of soluble intercellular adhesion molecule-1 (ICAM-1), soluble vascular cell adhesion molecule-1 (VCAM-1), and tumor necrosis factor alpha (TNF alpha) was measured by EIA (Bender Medsystems, Vienna, Austria), EIA (R&D Systems Inc., MN, USA), and ELISA (Japan Immunoresearch Laboratories Co. Ltd., Gunma, Japan), respectively.

#### Statistical analysis

Statistical analysis was performed using StatView 5.0 for Windows®. Paired t test, two-sample t indepen-

dent-group test, the Wilcoxon signed-rank test, and the Mann Whitney U test were used to compare each of the measured values of the basic level before the administration of DHEA and that after two weeks of administration. The Spearman ranking correlation coefficient was used to verify the correlation coefficient. A P value <0.05 was considered statistically significant.

## Results


### Change in hormone concentration in blood

Table 2 gives the hormone concentration before and after the DHEA administration. After administration of 25 mg DHEA for two weeks, the serum concentration of DHEA, DHEAS, and androstenedione exhibited a significant increase; however, IGF-1, E2, and testosterone showed no significant change. Because the basal level of the serum DHEA and DHEAS concentration decreases with age, subjects were divided into two groups according to their age. The subjects who were  $\leq 41$  years of age were classified into the younger group, and those  $>41$  years of age were classified into the older group. In the younger group, after two week administration of 25 mg DHEA, the serum concentration of DHEA and DHEAS exhibited a significant increase. In the older group, after two week administration of 25 mg DHEA, in addition to DHEA and DHEAS, the concentration of androstenedione and E2 exhibited a significant increase. For comparison of dosage effectiveness, we tested the administration of 50 mg DHEA as a preliminary study. Table 2 also gives the hormone concentration after the 50 mg DHEA administration. There were no differences in

Table 2.

Age (yr)	25 mg DHEA administered						50 mg DHEA administered	
	All (n = 22)		Younger (n = 10)		Older (n = 12)		(n = 6) 51.8 $\pm$ 7.5	
	41.1 $\pm$ 10.0		32.1 $\pm$ 5.5		48.4 $\pm$ 5.7		Baseline	2 weeks
	Baseline	2 weeks	Baseline	2 weeks	Baseline	2 weeks	Baseline	2 weeks
DHEA (nmol/l)	20.3 $\pm$ 11.3	29.6 $\pm$ 15.9 <sup>d</sup>	21.2 $\pm$ 14.4	27.1 $\pm$ 15.0 <sup>a</sup>	19.6 $\pm$ 8.5	31.8 $\pm$ 16.9 <sup>b</sup>	21.0 $\pm$ 5.3	33.1 $\pm$ 16.7
DHEAS ( $\mu$ mol/l)	7.3 $\pm$ 3.7	12.0 $\pm$ 4.0 <sup>f</sup>	8.1 $\pm$ 3.9	12.4 $\pm$ 2.8 <sup>e</sup>	6.6 $\pm$ 3.5	11.7 $\pm$ 5.0 <sup>e</sup>	5.3 $\pm$ 2.3	11.9 $\pm$ 4.2 <sup>b</sup>
Androstenedione (nmol/l)	7.9 $\pm$ 2.2	10.7 $\pm$ 2.7 <sup>e</sup>	8.3 $\pm$ 3.0	10.3 $\pm$ 3.1	7.6 $\pm$ 1.3	11.1 $\pm$ 2.4 <sup>e</sup>	6.8 $\pm$ 2.9	12.2 $\pm$ 4.5 <sup>a</sup>
Estradiol (pmol/l)	112 $\pm$ 50	118 $\pm$ 34	126 $\pm$ 64	106 $\pm$ 31	100 $\pm$ 34	127 $\pm$ 34 <sup>a</sup>	67 $\pm$ 25	85 $\pm$ 9
Testosterone (nmol/l)	16.6 $\pm$ 4.2	16.4 $\pm$ 4.5	17.0 $\pm$ 5.8	16.7 $\pm$ 5.6	16.3 $\pm$ 2.4	16.2 $\pm$ 3.7	12.9 $\pm$ 5.7	13.0 $\pm$ 3.5
IGF-1 (nmol/l)	24.9 $\pm$ 6.7	26.2 $\pm$ 7.7	28.7 $\pm$ 6.8	28.6 $\pm$ 6.6	21.7 $\pm$ 5.0	24.2 $\pm$ 8.3	22.5 $\pm$ 8.8	24.9 $\pm$ 6.6

Values are expressed as the mean  $\pm$  S.D. <sup>a</sup> P<0.05, <sup>b</sup> P<0.01, <sup>c</sup> P<0.005, <sup>d</sup> P<0.001, <sup>e</sup> P<0.0005, and <sup>f</sup> P<0.0001 compared with basal value



**Fig. 1.** Serum hormone levels before and after DHEA administration

a. Serum concentration of DHEA, DHEAS, androstenedione, estradiol, IGF-1, and testosterone before the DHEA administration (○). Serum concentration of DHEAS and estradiol was found to decrease significantly with age. b. Serum concentration of the same hormones after daily administration of 25 mg DHEA for two weeks (●). The decreases in DHEAS and E2 with age were no longer observed.

Table 3.

	All (n = 22)		Younger (n = 10)		Older (n = 12)	
	Baseline	2 weeks	Baseline	2 weeks	Baseline	2 weeks
Total cholesterol (mmol/l)	5.35 ± 1.18	5.29 ± 0.96	4.89 ± 1.11	5.66 ± 0.83	5.74 ± 1.14	5.65 ± 0.91
Triglyceride (mmol/l)	1.17 ± 0.68	0.95 ± 0.50	1.28 ± 0.67	1.00 ± 0.63	1.07 ± 0.70	0.92 ± 0.41
LDL cholesterol (mmol/l)	3.38 ± 1.02	3.24 ± 0.87	2.98 ± 0.97	2.90 ± 0.73	3.82 ± 0.94	3.61 ± 0.89
HDL cholesterol (mmol/l)	1.63 ± 0.43	1.64 ± 0.35	1.42 ± 0.25	1.48 ± 0.24	1.88 ± 0.47	1.82 ± 0.38

Values are expressed as the mean ± S.D.




Fig. 2. Correlation between serum concentration of DHEA and glucose tolerance. Correlation of the serum level of DHEA with the fasting plasma glucose, fasting serum insulin, insulinogenic index, and HOMA-R before (○) and after (●) the DHEA administration. The fasting insulin titer and HOMA-R values correlated negatively with the serum level of DHEA.

any of the hormone concentrations between the 25 mg and 50 mg DHEA administration.


When investigating the correlation between age and each serum hormone concentration before and after the DHEA administration, serum DHEAS and E2 were found to decrease significantly with age. After the administration of 25 mg DHEA for two weeks, such age related decrease in DHEAS and E2 disappeared. Although there was a tendency for the serum concentration of DHEA and androstenedione to decrease with age, it was not statistically significant (Fig. 1). The se-

rum hormone concentration of the older group was shown to increase to the same level as that of younger group for DHEA, DHEAS, androstenedione, and E2.

*Effect on routine examination*

After the administration of 25 mg DHEA for two weeks, there was no significant change in the complete blood count, liver function, renal function, electrolyte, or uric acid value (data not shown). In regard to the effect on lipids, there was no significant change in the





**Fig. 3.** Changes in HOMA-R among subjects whose serum DHEA level was elevated  
In subjects with a HOMA-R higher than two, there is a clear decrease in the HOMA-R level after the two week DHEA administration.

total cholesterol, LDL cholesterol, HDL cholesterol, or triglyceride concentration as indicated in Table 3.

#### *Effect on glucose metabolism*

After the administration of 25 mg DHEA for two weeks, there was no significant change in the fasting plasma glucose and fasting serum insulin level. During 75 g OGTT, there were no significant changes in the two-hour plasma glucose level, HOMA-R, or insulinogenic index. However, when comparing the relationship between each evaluation item and the DHEA concentration, regardless of before or after administration, we recognized a significant negative correlation between the serum DHEA concentration and the fasting insulin concentration or the HOMA-R (Fig. 2). This finding indicates that the lower the blood DHEA level became, the higher the insulin resistance. In 19 subjects, HOMA-R was calculated before and after the two week administration of DHEA. There were nine subjects whose serum concentration of DHEA was elevated to higher than 21.1 nmol/l, which was the same as the mean concentration of the younger subjects. When a change in serum concentration of DHEA was compared to that for HOMA-R in each subject, three subjects with marked insulin resistance whose HOMA-R level was higher than 2.0 showed a decline in the

HOMA-R level after 25 mg of DHEA administration as shown in Fig. 3. No constant tendency was observed in six normal insulin sensitivity subjects whose HOMA-R level was lower than 2.0. These findings suggest the possibility that when the serum concentration of DHEA exceeds a certain level as a result of hormone replacement therapy, insulin resistance reverts to normal (Fig. 3).

#### *Correlation of serum DHEA concentration to cytokines and adhesion molecules (Before and after DHEA administration)*

The relationship of the DHEA level to cytokines and adhesion molecules, which are thought to have a relationship with insulin resistance and atherosclerosis, were studied by determining leptin, adiponectin, hsCRP, TNF alpha, soluble ICAM-1, and soluble VCAM-1. There was a significant negative correlation between the serum DHEA concentration and the serum concentration of leptin and hsCRP as shown in Fig. 4. Furthermore, leptin exhibited a significant positive correlation with insulin, HOMA-R, and hsCRP, and a negative correlation with adiponectin as indicated in Fig. 5.




Fig. 4. Correlation of serum DHEA level with serum concentration of leptin, adiponectin and hsCRP before (○) and after (●) DHEA administration. The serum level of DHEA was found to correlate negatively with the serum concentration of leptin (a) and hsCRP (c).

**Discussion**

It is well known that the concentration of the male sex hormone decreases gradually with age, and discussion regarding the usefulness of hormone replacement

therapy is becoming widespread [24–26]. Maintaining health and preventing chronic diseases in an aging society are important issues facing advanced countries, and DHEA replacement therapy is anticipated to be a possible solution to these problems. In this study, not only DHEA or DHEAS, but also androstenedione and E2 exhibited a tendency to decrease with age, and through the 25 mg per day DHEA administration the decreased levels of these hormone concentrations recovered to the same level as that of the younger subjects. In reports up to now, there have been many examples of replacement studies using doses greater than 50 mg per day [27–36]. However, in this study, we selected 25 mg per day of DHEA administration because the standard dose of many clinically available medicines for Western people tends to be equivalent to the maximum dose for Japanese. It is thought that the administration of a low dose of DHEA might be safer. According to the change in older group’s hormone profiles, it is thought that even a 25 mg replacement regimen could be sufficient to obtain an increase in Japanese subjects. Further evaluation regarding the dose effectiveness is required.

In young subjects who exhibited a sufficiently high serum concentration of DHEA before the treatment, no significant change was observed after the 25 mg daily DHEA administration. This might be due to the extensive peripheral metabolism of the orally administered DHEA to other androgens and conjugates [37]. Together with the fact that there were no abnormal values from the blood test or biochemical examination, the above results support the notion that DHEA replacement therapy is safe [38]. However, since the administration was limited to a short two weeks in this study, future investigations are needed involving a low-dose long-term therapy and evaluation of the sex steroid hormone concentration in the blood and the side effects.

DHEA administration was reported to reduce visceral fat and to improve insulin resistance [39]. In the results of the 75 g OGTT administered this time, while there was no discernable influence on the plasma glucose level, we recognized the negative correlation between the serum DHEA concentration and the fasting insulin level or the HOMA-R. This is consistent with the previous report by Villareal and Holloszy [39].

In this investigation, we recognized that the serum DHEA concentration and the serum leptin concentration have a negative correlation, and this supports the




Fig. 5. Correlation of serum leptin level with insulin resistance and cytokines before (○) and after (●) DHEA administration. Positive correlations were observed between the serum leptin level with insulin (a), HOMA-R (b) and hsCRP (d). Negative correlation was observed between the serum leptin level with adiponectin (c).

results reported by Callies *et al.* [30]. The significant positive correlation between the serum concentration of leptin and the insulin resistance were consistent with the findings of Segal *et al.* [40]. The relationship between the serum DHEA concentration and the onset frequency of myocardial infarction was identified in previous reports [6, 41]. The results of the current study indicating that there is a negative correlation between the serum DHEA concentration and hsCRP is consistent with the results reported by Leal *et al.* [42]. According to these results, the serum concentration of DHEA and various factors that are involved in insulin resistance might influence each other [43]. However, the mechanism for the correlation is not clear and further investigation is needed.

In conclusion, the results of this short-term low-dose DHEA administration regimen suggest that supplemental DHEA administration to healthy middle-aged and elderly male subjects may help maintain their serum sex steroid hormone concentration at a younger age level without appreciable side effects. The low dosage of DHEA replacement therapy is expected to have the effect of improving insulin resistance.

#### Acknowledgement

This study was supported by the Research Grant for Longevity Sciences (12C-03) from the Ministry of Health, Labour and Welfare, Japan.

#### References

1. Lamberts SW, van den Beld AW, van der Lely AJ (1997) The endocrinology of aging. *Science* 278: 419–424.
2. Roth GS, Lane MA, Ingram DK, Mattison JA, Elahi D,

- Tobin JD, Muller D, Metter EJ (2002) Biomarkers of caloric restriction may predict longevity in humans. *Science* 297: 811.
3. Eich DM, Nestler JE, Johnson DE, Dworkin GH, Ko D, Wechsler AS, Hess ML (1993) Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. *Circulation* 87: 261–269.
  4. Gordon GB, Bush DE, Weisman HF (1988) Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. *J Clin Invest* 82: 712–720.
  5. Herrington DM (1995) Dehydroepiandrosterone and coronary atherosclerosis. *Ann NY Acad Sci* 774: 271–280.
  6. Herrington DM, Gordon GB, Achuff SC, Trejo JF, Weisman HF, Kwiterovich PO Jr, Pearson TA (1990) Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. *J Am Coll Cardiol* 16: 862–870.
  7. Aoki K, Saito T, Satoh S, Mukasa K, Kaneshiro M, Kawasaki S, Okamura A, Sekihara H (1999) Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phosphatase and fructose-1,6-bisphosphatase activities in C57BL/KsJ-db/db mice: comparison with troglitazone. *Diabetes* 48: 1579–1585.
  8. Coleman DL, Leiter EH, Schwizer RW (1982) Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. *Diabetes* 31:830–833.
  9. Ladriere L, Laghmich A, Malaisse-Lagae F, Malaisse WJ (1997) Effect of dehydroepiandrosterone in hereditarily diabetic rats. *Cell Biochem Funct* 15: 287–292.
  10. Du C, Khalil MW, Sriram S (2001) Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. *J Immunol* 167: 7094–7101.
  11. Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Scholmerich J, Falk W, Lang B (1998) Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. *J Clin Endocrinol Metab* 83: 2012–2017.
  12. Yu CK, Yang BC, Lei HY, Chen YC, Liu YH, Chen CC, Liu CW (1999) Attenuation of house dust mite *Dermatophagoides farinae*-induced airway allergic responses in mice by dehydroepiandrosterone is correlated with down-regulation of TH2 response. *Clin Exp Allergy* 29: 414–422.
  13. Kasperk CH, Wakley GK, Hierl T, Ziegler R (1997) Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro. *J Bone Miner Res* 12:464–471.
  14. Labrie F, Diamond P, Cusan L, Gomez JL, Belanger A, Candas B (1997) Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. *J Clin Endocrinol Metab* 82: 3498–3505.
  15. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG, Lopez AM (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. *JAMA* 290: 1739–1748.
  16. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. *JAMA* 290: 1729–1738.
  17. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenso JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A (2003) Breast cancer and non-steroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. *Cancer Res* 63: 6096–6101.
  18. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA* 288: 321–333.
  19. Kawano H, Yasue H, Kitagawa A, Hirai N, Yoshida T, Soejima H, Miyamoto S, Nakano M, Ogawa H (2003) Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. *J Clin Endocrinol Metab* 88: 3190–3195.
  20. Sugino M, Ohsawa N, Ito T, Ishida S, Yamasaki H, Kimura F, Shinoda K (1998) A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy. *Neurology* 51: 586–589.
  21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28: 412–419.
  22. Kosaka K, Kuzuya T, Hagura R, Yoshinaga H (1996) Insulin response to oral glucose load is consistently decreased in established non-insulin-dependent diabetes mellitus: the usefulness of decreased early insulin response as a predictor of non-insulin-dependent diabetes mellitus. *Diabet Med* 13: S109–119.
  23. Seltzer HS, Allen EW, Herron AL Jr, Brennan MT (1967) Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. *J Clin Invest* 46: